Earnings ·
Orthofix Medical Inc. reported second quarter 2026 financial results for the period ended June 30, 2026, announcing a…
OFIXOrthofix Medical Inc.
Orthofix Medical Inc. reported second quarter 2026 financial results for the period ended June 30, 2026, announcing a net loss of $15.8 million and non-GAAP adjusted EBITDA of $20.1 million. Reported net sales reached $210.9 million, reflecting 4% growth on a reported basis and 5% growth on a pro forma constant currency basis compared to the prior year period. The company raised its full-year 2026 guidance, increasing expected net sales to a range of $845 million to $855 million and adjusted EBITDA to $95 million to $98 million. Orthofix Medical Inc. operates in the medical technology industry, specializing in musculoskeletal solutions including spinal implants, biologics, limb reconstruction systems, and bone growth therapies.